Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 136

Sort by

Sort Order Select

Journal Articles

Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Locally Advanced or Metastatic Lung Cancer (LC) Receiving Chemotherapy

Kyaw Zin Thein, MDMBBS, Lukman Tijani, MD, Thein H. Oo, MD

Blood (2019) 134 (Supplement_1): 3466.

https://doi.org/10.1182/blood-2019-128561

Published: 2019

Journal Articles

Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Locally Advanced or Metastatic Lung Cancer Receiving Chemotherapy

Kyaw Zin Thein, MDMBBS, Lukman Tijani, MD, Thein H. Oo, MD

Blood (2019) 134 (Supplement_1): 2435.

https://doi.org/10.1182/blood-2019-123144

Published: 2019

Journal Articles

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Brandon Tse, Gloria Lim, MDFRCPC,MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc, Katerina Pavenski, MD

Blood (2019) 134 (Supplement_1): 2381.

https://doi.org/10.1182/blood-2019-123081

Published: 2019

Journal Articles

Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study

Siavash Piran, MDMSc,FRCPC, Michelle Zondag, BSN, RN, Drew Bednar, MD FRCSC, Brian Drew, MD FRCSC, Agnes Chmiel, MD FRCPC, Noel Chan, MBBS, MRCP, FRACP, FRCPA, John W. Eikelboom, MBBS, MSc, FRACP, FRCPA, Sam Schulman, MD PhD FRCPC

Blood (2019) 134 (Supplement_1): 2434.

https://doi.org/10.1182/blood-2019-124601

Published: 2019

Journal Articles

Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation

Guy Young, MD, Anthonie WA. Lensing, MD PhD, Paul Monagle, MBBS, MSc, Christoph Male, MD, Dagmar Kubitza, MD

Blood (2019) 134 (Supplement_1): 164.

https://doi.org/10.1182/blood-2019-124873

Published: 2019

Journal Articles

Direct Oral Anticoagulants Compared to Low Molecular Weight Heparin in the Treatment of Cancer-Associated Thromboembolism: An Updated Meta-Analysis of Randomized Controlled Trails

Sariya Wongsaengsak, MD, Somedeb Ball, MD, Nuvneet Khandelwal, MD, Alay Tikue, MD, Arunee Motes, Nusrat Jahan, MD, Kyaw Zin Thein, MDMBBS, Lukman Tijani, MD

Blood (2019) 134 (Supplement_1): 4962.

https://doi.org/10.1182/blood-2019-125473

Published: 2019

Journal Articles

Safe and Effective Use of Rivaroxaban for Treatment of Cancer Associated Venous Thromboembolic Disease

Gerald A. Soff, MD, Debra M. M Sarasohn, MD, Eva S Haegler-Laube, MD, Sean M Devlin, PhD, Yimei Miao, BS, Gemma Bendheim, BA, Jeanette Batista, RN, Jonathan Wills, Jodi V Mones, MD, Cy Wilkins, MD, Simon H Mantha, MD MPH

Blood (2018) 132 (Supplement 1): 2536.

https://doi.org/10.1182/blood-2018-99-115506

Published: 2018

Journal Articles

Cancer-Associated Thrombosis and Bleeding Risk in Gastrointestinal Malignancies with Apixaban and Rivaroxaban Compared to Low Molecular Weight Heparin

Damon E. Houghton, MD, Dalene M. Bott-Kitslaar, APRN, CNP, Emily Vargas, MPH, David O. Hodge, MS, Teresa R Lang, PA-C, Lisa Peterson, RN, Ana I Casanegra, MD, Robert D. McBane, MD, Waldemar E. Wysokinski, MD PhD, David A Froehling, MD

Blood (2018) 132 (Supplement 1): 362.

https://doi.org/10.1182/blood-2018-99-114185

Published: 2018

Journal Articles

Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial

Robert D. McBane, MD, Waldemar E. Wysokinski, MD PhD, Jennifer Le-Rademacher, PhD, Aneel A. Ashrani, MD, M.S., Alfonso J Tafur, MD MS, RPVI, FSVM, Krishna Gundabolu, MBBS, Juliana Perez-Botero, MD, Usha Perepu, MD, Daniel M. Anderson, MD MPH, Charles Kuzma, MD, Roberto leon Ferre, MD, Stanislav Henkin, MD, Charles Lenz, MD, Charles Loprinzi, MD

Blood (2018) 132 (Supplement 1): 421.

https://doi.org/10.1182/blood-2018-99-118808

Published: 2018

Journal Articles

Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)

Michael J. Kovacs, MD, Marc Rodger, MDMSc, Philip S. Wells, MDMSc,FRCP, Shannon M. Bates, MD MSc, Clive Kearon, MB, PhD, Mark Blostein, MDFRCPC, Alejandro Lazo-Langner, MD MSc, Susan Kahn, MD, Sam Schulman, MD PhD FRCPC, Elham Sabri, MSc, Susan Solymoss, MD, Timothy Ramsay, PhD, Luljeta Pallaveshi, RN, BA, David Anderson, MD

Blood (2018) 132 (Supplement 1): 424.

https://doi.org/10.1182/blood-2018-99-109964

Published: 2018

Journal Articles

Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism

Deborah Y. Park, BS, Shyam K. Poudel, MD, Xuefei Jia, MS, Mailey Lynn Wilks, CNP, MSN, APRN, Vicki Pinkava, MSBS, PA-C, Meghan O'Brien, MS, ANP-BC, Barbara Tripp, CNS,AOCN, Jung-Min Song, RN,CNS, Keith R. McCrae, MD, Dana E. Angelini, MD, Alok A. Khorana, MD

Blood (2018) 132 (Supplement 1): 1237.

https://doi.org/10.1182/blood-2018-99-111897

Published: 2018

Journal Articles

Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial

Annie Young, PhD, Andrea Marshall, PhD, Jennifer Thirlwall, BSc, Catherine Hill, BSc, Danielle Hale, MA, Janet Dunn, PhD, Anand Lokare, MD FRCPath, MRCP, Ajay K. Kakkar, MBBS, Mark N. Levine, MD MSC, Oliver Chapman, MBBS, FRCPath, MRCP

Blood (2017) 130 (Supplement 1): 625.

https://doi.org/10.1182/blood.V130.Suppl_1.625.625

Published: 2017

Journal Articles

Tissue Factor-Related Biomarkers and Prediction of Cancer-Associated VTE: Correlative Analyses of the Phacs Trial

Alok A. Khorana, MD, Nigel Mackman, PhD, Yohei Hisada, PhD, Cihan Ay, MD, Derick Peterson, Charles W. Francis, MD, Andrea Baran, MS

Blood (2017) 130 (Supplement 1): 1096.

https://doi.org/10.1182/blood.V130.Suppl_1.1096.1096

Published: 2017

Journal Articles

Prophylactic Effects of Recombinant Thrombomodulin Against Sclerodermatous Chronic Graft-Versus-Host Disease in a Rodent Model

Toshihiro Fujiki, MD, Rie Kuroda, MD, Hideaki Maeba, MD, Kazuhiro Noguchi, MD, Masaki Fukuda, MD, Shintaro Mase, MD, Raita Araki, MD, Yasuhiro Ikawa, MD PhD, Akihiro Yachie, MD PhD, Masayuki Nagasawa, MD PhD, Ryosei Nishimura, MD PhD

Blood (2017) 130 (Supplement 1): 1895.

https://doi.org/10.1182/blood.V130.Suppl_1.1895.1895

Published: 2017

Journal Articles

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Gary E. Raskob, PhD, Nick Van Es, MD, Peter Verhamme, MD PhD, Marc Carrier, MD, Marcello Di Nisio, MD, David A. Garcia, MD, Michael A. Grosso, MD, Ajay K. Kakkar, MBBS, Michael J. Kovacs, MD, Michele F. Mercuri, MD PhD FAHA, Guy Meyer, MD, Annelise Segers, MD, Minggao Shi, PhD, Tzu-Fei Wang, MD, Erik Yeo, MD FACP, FRCPC, George Zhang, PhD, Jeffrey I. Zwicker, MD, Jeffrey I. Weitz, MD, Harry R. Büller, MD PhD

Blood (2017) 130 (Supplement 1): LBA-6.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-6.LBA-6

Published: 2017

Journal Articles

The Use of Thromboelastography in Monitoring Coagulation Status for Patients Treated with Low Molecular Weight Heparin, Warfarin, Apixaban, and Rivaroxaban

Debbie Jiang, MD, Anne Dumont, RN, Adrienne J. Burns, MMS, PA-C, Henry Rinder, MD, Christopher A. Tormey, MD, Alfred Lee, MD PhD

Blood (2017) 130 (Supplement 1): 3741.

https://doi.org/10.1182/blood.V130.Suppl_1.3741.3741

Published: 2017

Journal Articles

Anticoagulant Prescription Patterns for Cancer Associated Thrombosis: New Insights into the Use of Direct Oral Anticoagulants

Dana E. Angelini, MD, Paul Elson, PhD, Keith McCrae, MD, Alok A. Khorana, MD

Blood (2017) 130 (Supplement 1): 4725.

https://doi.org/10.1182/blood.V130.Suppl_1.4725.4725

Published: 2017

Journal Articles

An Individual Participant Data Meta-Analysis of 13 Randomized Trials to Evaluate the Impact of Prophylactic Use of Heparin in Oncological Patients

Blood (2017) 130 (Supplement 1): 626.

https://doi.org/10.1182/blood.V130.Suppl_1.626.626

Published: 2017

Journal Articles

The Khorana Score for the Prediction of Venous Thromboembolism in Patients with Solid Cancer: An Individual Patient Data Meta-Analysis

Blood (2017) 130 (Supplement 1): 627.

https://doi.org/10.1182/blood.V130.Suppl_1.627.627

Published: 2017

Journal Articles

Post-Thrombotic Syndrome and Functional Disability in Patients with Upper Extremity Deep Vein Thrombosis: A Prospective Cohort Study

Alejandro Lazo-Langner, MD MSc, FRCPC, Susan R Kahn, MD MSc, Philip S Wells, MD, David Anderson, MD, Marc Rodger, MD MSc, Marc Carrier, MD MSc, FRCPC, Annmarie A. Bosco, MBBS, BSc (MD, Judy Kovacs, RN, Roweena Corpuz, RN, Michael J. Kovacs, MD FRCPC

Blood (2016) 128 (22): 417.

https://doi.org/10.1182/blood.V128.22.417.417

Published: 2016

NARROW

Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Locally Advanced or Metastatic Lung Cancer (LC) Receiving Chemotherapy

Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Locally Advanced or Metastatic Lung Cancer Receiving Chemotherapy

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study

Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. an Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation

Direct Oral Anticoagulants Compared to Low Molecular Weight Heparin in the Treatment of Cancer-Associated Thromboembolism: An Updated Meta-Analysis of Randomized Controlled Trails

Safe and Effective Use of Rivaroxaban for Treatment of Cancer Associated Venous Thromboembolic Disease

Cancer-Associated Thrombosis and Bleeding Risk in Gastrointestinal Malignancies with Apixaban and Rivaroxaban Compared to Low Molecular Weight Heparin

Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial

Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)

Clinical Outcomes with Direct Oral Anticoagulants Compared to Low Molecular Weight Heparins in the Treatment of Cancer-Associated Venous Thromboembolism

Anticoagulation Therapy in Selected Cancer Patients at Risk of Recurrence of Venous Thromboembolism: Results of the Select-D™ Pilot Trial

Tissue Factor-Related Biomarkers and Prediction of Cancer-Associated VTE: Correlative Analyses of the Phacs Trial

Prophylactic Effects of Recombinant Thrombomodulin Against Sclerodermatous Chronic Graft-Versus-Host Disease in a Rodent Model

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

The Use of Thromboelastography in Monitoring Coagulation Status for Patients Treated with Low Molecular Weight Heparin, Warfarin, Apixaban, and Rivaroxaban

Anticoagulant Prescription Patterns for Cancer Associated Thrombosis: New Insights into the Use of Direct Oral Anticoagulants

An Individual Participant Data Meta-Analysis of 13 Randomized Trials to Evaluate the Impact of Prophylactic Use of Heparin in Oncological Patients

The Khorana Score for the Prediction of Venous Thromboembolism in Patients with Solid Cancer: An Individual Patient Data Meta-Analysis

Post-Thrombotic Syndrome and Functional Disability in Patients with Upper Extremity Deep Vein Thrombosis: A Prospective Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only